Atricure opened higher at $57.93, compared with its previous close of $57.53. In the last trading session, the stock traded between $55.74 and $58.24. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Atricure is now worth
$ 71.45
Resulting in a loss of
$ 28.55 (28.55%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 8 Analysts
Buy
75%
Hold
25%
Sell
0%
Markets Today
Today's Change
$-1.56 (-2.71%)
Day High
$58.24
Day Low
$55.74
Day Open
$57.93
Prev Close
$57.53
Volume
3,40,141
1W Return
-14.54%
1M Return
-2.30%
3M Return
30.30%
6M Return
112.81%
1Y Return
70.33%
Fundamentals
Market Cap ($ Mn)
2,850
PE Ratio
231.14
PB Ratio
4.78
PEG Ratio
-
ROE
-2.44%
ROCE
-1.60%
EPS (TTM)
$0.08
Investment Returns
1 Week
-14.54%
1 Month
-2.30%
3 Months
30.30%
6 Months
112.81%
9 Months
70.14%
Financials
Quarterly
All values in $ Mn
136.1
Jun 25
134.3
Sep 25
140.5
Dec 25
141.2
Mar 26
153.6
Jun 26
154.4
Sep 26
Updates
5Nov
Canaccord Genuity raises AtriCure price target to $67
Canaccord Genuity raised AtriCure's price target from $55 to $67. The firm maintained its Buy rating on the stock. Analyst William Plovanic issued the revised valuation.
AtriCure reported Q3 EPS of 17 cents, beating consensus estimate of a loss of 5 cents. Quarterly sales reached $154.450 million, surpassing the $151.217 million consensus estimate. FY26 adjusted EPS guidance raised to 40 cents-46 cents from 24 cents-32 cents. BTIG and Needham raised price targets to $70, maintaining Buy ratings.
8 days ago
4Nov
AtriCure Q3FY26 Results: Revenue up 15% to $154.5 million
Revenue rose 15% YoY to $154.5 million, driven by 17% growth in U.S. business. Net income turned positive at $4.1 million vs. $0.3 million loss in prior year. Adjusted EBITDA surged 50.6% to $26.8 million; gross margin improved 180 bps to 77.3%. Pain management franchise grew 33% worldwide; CryoXT surpassed $1 million in quarterly revenue. Full-year FY26 revenue guidance set at $606–$610 million with raised EBITDA outlook.
9 days ago
25Aug
AtriCure to participate in 2026 Wells Fargo Health Care Conference
AtriCure (NASDAQ: ATRC) to participate in 2026 Wells Fargo Health Care Conference. Management scheduled for fireside chat on September 8, 2026, at 10:15 am ET. Live audio webcast available via company investor relations website.
2mo ago
2Jul
AtriCure to announce second quarter 2026 financial results
AtriCure, Inc. will announce its second quarter 2026 financial results on July 23, 2026, followed by an audio webcast at 4:30 p.m. Eastern Time. The company specializes in surgical treatments for atrial fibrillation and related conditions. Participants can register online for the webcast, and a replay will be available.
